Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04932096
Other study ID # GPEDI1282A
Secondary ID 1K23HL150229-01A
Status Recruiting
Phase Phase 2
First received
Last updated
Start date January 2, 2023
Est. completion date August 31, 2025

Study information

Verified date November 2023
Source Oregon Health and Science University
Contact Cydni N Williams, MD
Phone 503-494-5522
Email willicyd@ohsu.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Sleep wake disturbances compound recovery in over half of pediatric traumatic brain injury survivors, leading to impaired quality of life, and few effective interventions exist to treat this important morbidity. Therefore, this study will conduct a randomized controlled trial evaluating a melatonin intervention started during hospitalization and continued after discharge compared to placebo. The trial will investigate if this intervention is feasible, acceptable, and effective at reducing sleep wake disturbances as measured on the Sleep Disturbances Scale for Children 1-month after hospital discharge. Participants will be randomly assigned to receive the intervention (melatonin) or to the control group (placebo) with a goal of equal numbers of participants in each group and all will receive sleep education. Participants will be followed closely after consent and outcomes will be assessed at hospital discharge, and 1-month. Outcomes will focus on feasibility (ability to recruit patients into the trial) and acceptability (patient safety and satisfaction), but will also assess the effectiveness of the intervention to reduce sleep disturbances after discharge. The investigators will assess sleep using questionnaires and actigraphy (watch-like activity monitors). Exploratory outcomes will include global health outcomes.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date August 31, 2025
Est. primary completion date July 1, 2025
Accepts healthy volunteers No
Gender All
Age group 6 Years to 18 Years
Eligibility Inclusion: - Children age =6 years and <19 years - Traumatic brain injury defined as disruption of the normal function of the brain resulting from blunt force injury with a severity defined as mild complicated, moderate, or severe by the Glasgow Coma Scale with the presence of intracranial injury on imaging - Admission to Oregon Health & Science University Hospitals - Deemed likely to survive hospitalization by clinical care team - Able to tolerate enteral medications within 72 hours of admission - Child participant resides with parent or legal guardian Exclusion: - Lack stable means of communication with study team (phone, email, mailing address) - Abusive trauma suspected or confirmed - Dialysis - Extracorporeal support (e.g. ECMO) - Significant liver injury defined as >2x normal levels for AST or ALT - Clinical team safety concerns with use of intervention - Pregnancy - Prisoners

Study Design


Intervention

Drug:
melatonin
melatonin supplementation
Other:
placebo
microcrystalline cellulose filled capsule

Locations

Country Name City State
United States Oregon Health & Science University Portland Oregon

Sponsors (2)

Lead Sponsor Collaborator
Oregon Health and Science University National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Luther M, Poppert Cordts KM, Williams CN. Sleep disturbances after pediatric traumatic brain injury: a systematic review of prevalence, risk factors, and association with recovery. Sleep. 2020 Oct 13;43(10):zsaa083. doi: 10.1093/sleep/zsaa083. — View Citation

Poppert Cordts KM, Hall TA, Hartman ME, Luther M, Wagner A, Piantino J, Guilliams KP, Guerriero RM, Jara J, Williams CN. Sleep Measure Validation in a Pediatric Neurocritical Care Acquired Brain Injury Population. Neurocrit Care. 2020 Aug;33(1):196-206. doi: 10.1007/s12028-019-00883-5. — View Citation

Williams CN, Hartman ME, McEvoy CT, Hall TA, Lim MM, Shea SA, Luther M, Guilliams KP, Guerriero RM, Bosworth CC, Piantino JA. Sleep-Wake Disturbances After Acquired Brain Injury in Children Surviving Critical Care. Pediatr Neurol. 2020 Feb;103:43-51. doi: 10.1016/j.pediatrneurol.2019.08.010. Epub 2019 Aug 26. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other reason for non-adherence qualitative response to survey question about reasons for non-compliance with treatment regimen or sleep plan 1-month
Other health related quality of life Pediatric Quality of Life Inventory (PedsQL): parent reported measure of quality of life. Scores range 0-100 with higher scores indicating better quality of life. 1-month
Other cognitive functioning Behavior Rating Inventory of Executive Function, second edition (BRIEF-2); parent proxy report of everyday executive function, reported as standardized Global Executive Composite T-score, with higher scores indicating worse function. T-scores range from 0-100, with a mean of 50 and standard deviation of 10. 1-month
Other physical functioning Functional Status Scale, range 6-30, with higher scores indicating worse function 1-month
Other anxiety Patient Reported Outcome Measurement Information System (PROMIS) anxiety short form T-score with higher scores indicating worse outcome. T-scores range from 0 - 100, with a mean of 50 and standard deviation of 10. 1-month
Other depression Patient Reported Outcome Measurement Information System (PROMIS) depression short form T-score with higher scores indicating worse outcome. T-scores range from 0-100, with a mean of 50 and standard deviation of 10. 1-month
Other pain Patient Reported Outcome Measurement Information System (PROMIS) pain intensity (raw score out of 10), and pain behavior (T-score with mean of 50 and standard deviation of 10) parent report forms; Higher scores indicate worse pain outcomes 1-month
Primary sleep disturbance Sleep Disturbances Scale for Children: 26-item parent proxy sleep questionnaire with higher scores reflecting greater disturbance and risk for clinically important sleep disorders. Each question is scored 1 through 5 for a range of possible total scores of 26 - 130. 1-month
Primary Recruitment Quantitative number of patients consented per patients approached through study completion, an average of 6-months
Primary Retention Quantitative number of participants completing trial procedures per patients consented through study completion, an average of 6-months
Secondary adherence quantitative pill counts 1-month
Secondary adherence qualitative participant report of compliance with treatment regimen evaluated by survey question estimating percentage of study days compliant with intervention 1-month
Secondary Fatigue Pediatric Quality of Life Inventory Multidimensional Fatigue Scale (PedsQL MFS); 18 item parent proxy report of fatigue. Scores range 0-100 with higher scores indicating better function and less fatigue. 1-month
Secondary Chronotype Children's Chronotype Questionnaire, parent reported survey of circadian rhythm characteristics. Each item assessed independently. 1-month
Secondary sleep latency actigraphy measured time in minutes to fall asleep 1-month
Secondary total sleep time actigraphy measured total time asleep in minutes 1-month
Secondary wake after sleep onset actigraphy measured time in minutes awake after sleep onset 1-month
Secondary number of night awakenings actigraphy measured number of instances awoken after sleep onset 1-month
Secondary sleep efficiency actigraphy measure percentage of nighttime period spent asleep 1-month
Secondary sleep onset time of day fell asleep 1-month
Secondary sleep offset time of day waking from nighttime sleep 1-month
Secondary adverse events time 0 Evaluation of adverse events asking participants to report any side effects of study interventions hospital discharge assessed up to 7 days
Secondary adverse events time 1 Evaluation of adverse events asking participants to report any side effects of study interventions 1-month
See also
  Status Clinical Trial Phase
Completed NCT04551508 - Delirium Screening 3 Methods Study
Recruiting NCT06037928 - Plasma Sodium and Sodium Administration in the ICU
Completed NCT03671447 - Enhanced Recovery After Intensive Care (ERIC) N/A
Recruiting NCT03941002 - Continuous Evaluation of Diaphragm Function N/A
Recruiting NCT04674657 - Does Extra-Corporeal Membrane Oxygenation Alter Antiinfectives Therapy Pharmacokinetics in Critically Ill Patients
Completed NCT04239209 - Effect of Intensivist Communication on Surrogate Prognosis Interpretation N/A
Completed NCT05531305 - Longitudinal Changes in Muscle Mass After Intensive Care N/A
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Completed NCT02916004 - The Use of Nociception Flexion Reflex and Pupillary Dilatation Reflex in ICU Patients. N/A
Recruiting NCT05883137 - High-flow Nasal Oxygenation for Apnoeic Oxygenation During Intubation of the Critically Ill
Completed NCT04479254 - The Impact of IC-Guided Feeding Protocol on Clinical Outcomes in Critically Ill Patients (The IC-Study) N/A
Recruiting NCT04475666 - Replacing Protein Via Enteral Nutrition in Critically Ill Patients N/A
Not yet recruiting NCT04538469 - Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff
Not yet recruiting NCT04516395 - Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae N/A
Withdrawn NCT04043091 - Coronary Angiography in Critically Ill Patients With Type II Myocardial Infarction N/A
Recruiting NCT02922998 - CD64 and Antibiotics in Human Sepsis N/A
Recruiting NCT02989051 - Fluid Restriction Keeps Children Dry Phase 2/Phase 3
Completed NCT03048487 - Protein Consumption in Critically Ill Patients
Completed NCT02899208 - Can an Actigraph be Used to Predict Physical Function in Intensive Care Patients? N/A
Recruiting NCT02163109 - Oxygen Consumption in Critical Illness